Lesson plan

Etrabamine

Etrabamine ( ; developmental code name JL-14839 or 14.839JL), also known as 6-methylamino-4,5,6,7-tetrahydrobenzothiazole, is a dopamine receptor agonist which was under development for the treatment of Parkinson's disease but was never marketed. It is taken orally. The drug shows affinity for the dopamine D 2 and D 3 receptors (K i = 2,620 nM and 300 nM, both for L -etrabamine). It acts as a dopamine D 2 and D 3 receptor agonist and does not appear to act as an agonist of the dopamine D 1 receptor. Etrabamine produces stereotypy in rodents and to a greater extent than apomorphine. This can be blocked by the dopamine antagonists sulpiride, haloperidol, and pimozide. It reverses the hypolocomotion induced by the dopamine depleting agent reserpine in rodents. The drug reduces levels of dopamine metabolites in the striatum in rodents. It strongly suppresses prolactin levels in rodents. The chemical synthesis of etrabamine has been described. The chemical structure of etrabamine was unlike that of other dopamine receptor agonists when it was first developed in the 1980s. Subsequently, pramipexole, a closely related derivative of etrabamine, was developed and introduced for the treatment of Parkinson's disease. Pramipexole shows 2.7- and 29-fold higher affinity for the dopamine D 2 and D 3 receptors than etrabamine, respectively.…

Back to article

Article summary

Etrabamine ( ; developmental code name JL-14839 or 14.839JL), also known as 6-methylamino-4,5,6,7-tetrahydrobenzothiazole, is a dopamine receptor agonist which was under development for the treatment of Parkinson's disease but was never marketed. It is taken orally. The drug shows affinity for the dopamine D 2 and D 3 receptors (K i = 2,620 nM and 300 nM, both for L -etrabamine). It acts as a dopamine D 2 and D 3 receptor agonist and does not appear to act as an agonist of the dopamine D 1 receptor. Etrabamine produces stereotypy in rodents and to a greater extent than apomorphine. This can be blocked by the dopamine antagonists sulpiride, haloperidol, and pimozide. It reverses the hypolocomotion induced by the dopamine depleting agent reserpine in rodents. The drug reduces levels of dopamine metabolites in the striatum in rodents. It strongly suppresses prolactin levels in rodents. The chemical synthesis of etrabamine has been described. The chemical structure of etrabamine was unlike that of other dopamine receptor agonists when it was first developed in the 1980s. Subsequently, pramipexole, a closely related derivative of etrabamine, was developed and introduced for the treatment of Parkinson's disease. Pramipexole shows 2.7- and 29-fold higher affinity for the dopamine D 2 and D 3 receptors than etrabamine, respectively.…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.